Marimed (MRMD) Current Deferred Revenue (2011 - 2026)

Marimed (MRMD) posted quarterly Current Deferred Revenue of $1.5 million for Q1 2026, up 5.67% quarter-over-quarter from $1.4 million in Q4 2025.

Marimed (MRMD) Current Deferred Revenue (2011 - 2026) Analysis & Trends

Marimed (MRMD) has reported Current Deferred Revenue for 12 consecutive years, with $1.5 million the latest figure, recorded in Q1 2026.

In Q1 2026, Current Deferred Revenue changed N/A year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $1.5 million (changed N/A YoY), while the FY2025 annual figure was $1.4 million, up 4.89% from the prior year.
Current Deferred Revenue climbed to $1.5 million in Q1 2026 per MRMD's latest filing, from $1.4 million in the prior quarter.
Across five years, Current Deferred Revenue topped out at $1.7 million in Q3 2025 and bottomed at $1.3 million in Q4 2024.
Historically, Current Deferred Revenue has averaged $1.5 million across 3 years, with a median of $1.4 million in 2025.
On a YoY basis, Current Deferred Revenue climbed as much as 4.89% in 2025 and fell as far as 4.89% in 2025.
Marimed's Current Deferred Revenue stood at $1.3 million in 2024, then grew by 4.89% to $1.4 million in 2025, then rose by 5.67% to $1.5 million in 2026.
Business Quant data shows MRMD's Current Deferred Revenue at $1.5 million in Q1 2026, $1.4 million in Q4 2025, and $1.7 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.91 Bn	42.95 Bn	-
2	Teva Pharmaceutical Industries	42.98 Bn	39.32 Bn	2.15 Bn
3	Zoetis	31.53 Bn	29.86 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.61 Bn	22.81 Bn	5.10 Bn
5	United Therapeutics	22.16 Bn	19.49 Bn	683.80 Mn
6	Viatris	18.74 Bn	17.85 Bn	1.46 Bn
7	Neurocrine Biosciences	15.51 Bn	15.12 Bn	935.80 Mn
8	Elanco Animal Health	11.76 Bn	11.23 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.12 Bn	9.95 Bn	-
10	Marimed	27.77 Mn	19.33 Mn	16.23 Mn

Download Data